The human growth hormone or somatotropin helps to stimulate growth, regeneration, and reproduction. The increase in applications of growth hormone and the awareness about the effects of growth hormone in the treatment of short stature are major factors propelling the market growth. Most companies are investing in R&D for developing a growth hormone that has fewer side effects and will be long-acting hormonal therapy. Technical developments in the recombinant human growth hormone are also expected to boost the growth of the human growth hormone market, over the forecast period.
Key Market Trends
Turner Syndrome Segment is Expected to Register a Steady Growth
Turner syndrome is a rare chromosomal disorder that affects females. It is characterized by the partial or complete loss of one of the X chromosomes. The symptoms of Turner syndrome include a wide neck and a low or indistinct hairline, a tendency to develop high blood pressure, minor eye problems, drooping of the eyelids, and an under-active thyroid gland. The age of diagnosis has been decreasing with better awareness of Turner's syndrome in the medical community, which, in turn, is driving the market studied. Since it is associated with many complications related to heart, hearing loss, autoimmune disorders, mental health issues, infertility, and pregnancy complications, the demand for treatment involving growth hormones is increasing.
North America to Dominate the Market
The United States accounted for the largest market share. The dominance of this country can be attributed to factors, such as high healthcare expenditure and the availability of reimbursements. In the United States, approximately one in 4,000 to 10,000 children suffer from growth hormone deficiency and approximately 50,000 adults have a growth hormone deficiency, with about 6,000 new adult patients diagnosed every year. Recombinant growth hormone has been widely available for prescription use in the United States. It is used for growth hormone deficiency (GHD), Turner's syndrome, chronic renal insufficiency, gestational age or intrauterine growth retardation, Prader-Willi syndrome, and continued height deficit at puberty, and cachexia, or AIDS wasting.
Asia-Pacific is anticipated to witness the fastest growth, during the forecast period, as the demand for growth hormones has been rising in the emerging countries, for the past few years.
The human growth hormone market is consolidated and highly competitive, with a few market players controlling a significant market share. Furthermore, there are several active partnerships for the development of more efficacious and long-acting subtypes of human growth hormones.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support